Madrigal Pharmaceuticals Surges After Positive Test Results
Dec 19, 2022 By MarketDepth
Madrigal Pharmaceuticals (MDGL:NYQ) stock is up 250% intraday on successful results from its Liver Disease trials. The company has been working on a late-stage clinical trial to treat liver disease, which prompted the surge in price. The company is off to its biggest day in its history on the news.
Madrigal stock was hovering around the $80 mark for the year and climbed over 250% to $224 intraday.
The company caused many competitors in the space to lift off in price as demand for life-saving treatments climb. Madrigal has put itself into the spotlight as a competitor in pharmaceuticals.
